Investor Presentaiton

DSA Segment Drug discovery research, development, and regulatory-required safety testing of potential new drugs 100 Preclinical drug candidates discovered for clients since 1999 . Discovery Services Single source of services for discovering and characterizing novel drug candidates for preclinical development Early discovery, in vivo, and in vitro capabilities • Expertise in most major therapeutic areas, with a focus on oncology and CNS Broad capabilities across small and large molecule, antibody, and C&GT Expertise in integrated programs Ability to engage with clients at any stage of their discovery or early-stage development programs • . Safety Assessment (SA) Full suite of safety studies required for regulatory submission on a global basis across all therapeutic areas Global leader in both non-regulated and regulated (GLP) outsourced SA services Broad scientific capabilities General and specialty toxicology, bioanalysis, pathology, safety pharmacology, drug metabolism, and pharmacokinetics (DMPK) services Largest specialty toxicology offering from inhalation and infusion to developmental and reproductive toxicology -30% Outsourced SA share*, with next largest competitor at 12% -30 DSA sites worldwide ensure proximity to clients A safety assessment program costs 5x-10x less than a late-stage clinical program, providing incentive for clients to focus R&D spending on IND achievement Charles River Laboratories (CRL) Note: CRL market share data based on management estimates and publicly available information. *Safety Assessment market sector size definition has expanded (and CRL share updated) to fully reflect preclinical bioanalysis and chem & agchem sectors. 10

View entire presentation